Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Galmed Pharmaceuticals Q1 EPS $(0.62) Beats $(0.89) Estimate

Author: Benzinga Newsdesk | May 22, 2025 07:13am
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.89) by 30.34 percent. This is a 70.48 percent increase over losses of $(2.10) per share from the same period last year.

Posted In: GLMD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist